Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Genelux Corporation
Modality
gene_therapy
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05281471CT.gov Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fallopian Tube Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olvimulogene Nanivacirepvec (this asset) | Genelux Corporation | P3 | CCC · 52 |
| Mirvetuximab Soravtansine | AbbVie | P3 | BB |
| Adriamycin | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Carboplatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Irinotecan | Tianjin Medical University Cancer Institute and Hospital | P3 | BB |
| Nogitecan | Sichuan Baili Pharmaceutical Co., Ltd. | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | GOG Foundation | P3 | BB |
| Epirubicin | OncoC4, Inc. | P3 | BB |
| Glutathione | Alliance for Clinical Trials in Oncology | P3 | BB |
+42 more in the Fallopian Tube Cancer cohort
Other indications for Olvimulogene Nanivacirepvec
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Endometrioid Adenocarcinoma | — | P3 | B · 60 |
| Ovarian Serous Adenocarcinoma | — | P3 | B · 60 |
| Ovarian Cancer | — | P3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olvimulogene Nanivacirepvec in Fallopian Tube Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olvimulogene-nanivacirepvec-fallopian-tube-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →